Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) Given Average Recommendation of “Moderate Buy” by Brokerages

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) has been given an average recommendation of “Moderate Buy” by the six analysts that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and four have given a buy recommendation to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $20.00.

Several equities research analysts recently commented on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Nanobiotix in a research report on Thursday, January 22nd. Leerink Partners restated an “outperform” rating on shares of Nanobiotix in a report on Tuesday, November 25th. Wall Street Zen upgraded shares of Nanobiotix to a “hold” rating in a research note on Saturday, October 25th. Guggenheim boosted their target price on shares of Nanobiotix from $8.00 to $26.00 and gave the company a “buy” rating in a research report on Friday. Finally, HC Wainwright restated a “buy” rating on shares of Nanobiotix in a report on Tuesday, November 4th.

Nanobiotix Stock Down 0.9%

Nanobiotix stock opened at $20.85 on Friday. The stock’s 50 day moving average is $21.64 and its 200 day moving average is $17.40. Nanobiotix has a one year low of $2.95 and a one year high of $30.35.

Institutional Investors Weigh In On Nanobiotix

An institutional investor recently bought a new position in Nanobiotix stock. Optiver Holding B.V. purchased a new position in shares of Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 5,356 shares of the company’s stock, valued at approximately $101,000. 38.81% of the stock is currently owned by institutional investors and hedge funds.

About Nanobiotix

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.